Studies open for recruitment



Liver Studies


1. Protocol: 747-303 (PI: Dr Mark McCullen)
Short Title: The REGENERATE Study.

Protocol Title: A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis.

Lay Title: Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)

Click here for more information


2. Protocol: 3152-301-002 (PI: Dr Darrell Crawford)
Short Title: The AURORA Study.

Protocol Title: A Phase 3 Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis

Lay Title: Phase 3 Study for the Efficacy and Safety of CVC for the Treatment of Liver Fibrosis in Adults With NASH (AURORA)
3. Protocol: LJ401-HH01 (PI: Dr Darrell Crawford)

Protocol Title: A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study with LJPC-401 for the Treatment of Iron Overload in Adult Patients with Hereditary Hemochromatosis

Lay Title: A Study of LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis

Click here for more information


4. Protocol: 747-304 (PI: Dr Mark McCullen)
Short Title: The REVERSE Study.

Protocol Title: A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis

Lay Title: Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (REVERSE)

Click here for more information



5. Protocol: LM011-018-01 (PI: Dr Darrell Crawford)

Protocol Title: An open-label study to assess the efficacy and safety of LM011 in subjects diagnosed with Non-Alcoholic Steatohepatitis (NASH)

Lay Title: Effectiveness and safety of LM011 in treating subjects diagnosed with non-alcoholic steatohepatitis (NASH).
Click here for more information



Oncology Studies


1. PROTOCOL: AB928CSP0005 (PI: Dr Warren Joubert)
Protocol Title: A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Advanced Malignancies
Lay Title: Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies 
2. Protocol: MK-3475-022. KEYNOTE-022 (PI: Dr Victoria Atkinson)
Short Title: The KEYNOTE-022  study
Protocol Title: A Phase I/II Study to Assess the Safety and Efficacy of MK-3475 in Combination with Trametinib and Dabrafenib in Subjects with Advanced Melanoma.

Lay Title: A study to investigate MK-3475 (pembrolizamab) in combination with trametinib and dabrafenib in patients with advanced melanoma.
Click here for more information


3. Protocol: CK-101-101 (PI: Dr Ken O’Byrne)
Protocol Title: A Phase I/II, Open-Label, Safety, Pharmacokinetic and Efficacy Study of Ascending Doses of Oral CK-101 in Patients With Advanced Solid Tumors

Lay Title: Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors
Click here for more information


4. Protocol: INCAGN 1876-201 (PI: Dr Warren Joubert)
Protocol Title: A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

Lay Title: A Clinical trial with the purpose to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies in subjects with advanced or metastatic malignancies.
Click here for more information



5. Protocol: 2125-MEL-301(PI: Dr Victoria Atkinson)
Short Title: The ILLUMINATE 301 study

Protocol Title: A Randomized Phase 3 Comparison of IMO-2125 with Ipilimumab versus Ipilimumab Alone in Subjects with Anti-PD-1 Refractory Melanoma

Lay Title: A Phase 3 comparison of ipilimumab with and without IMO-2125 in advanced melanoma
Click here for more information


6. Protocol: I8X-MC-JECA (Part B & C) (PI: Dr Victoria Atkinson)
Protocol Title: A Phase 1 Study of LY3200882 in Patients with Solid Tumors

Lay Title: A Phase 1 Study of LY3200882 in Patients with Solid Tumors
Click here for more information


7. Protocol: (D081SC00001) (PI: Dr Pretoria Bilinski)
Short Title: The PROpel study

Protocol Title: A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (PROpel Study)

Lay Title: Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

Click here for more information



8. Protocol: (MK3475-495) (PI: Dr Ken O’Byrne)
Short Title: KEYNOTE-495; KeyImPaCT

Protocol Title: A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab-(MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT)

Lay Title: A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495)
Click here for more information


9 . Protocol: (CACZ885V2301) (PI: Dr Ken O’Byrne)
Short Title: CANOPY-2

Protocol Title: A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Canakinumab in Combination With Docetaxel Versus Placebo in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancer (NSCLC) Previously Treated With PD-(L)1 Inhibitors and Platinum-based Chemotherapy (CANOPY 2)

Lay Title: Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy
Click here for more information




Respiratory  Studies


1. Protocol: Z7224L01 (PI: Dr Rachel Thomson)
Short Title: The PROMIS I Study

Protocol Title: A Double-blind, Placebo-controlled, Multi-centre, Clinical Trial to Investigate the Efficacy and Safety of 12 Months of Therapy With Inhaled Colistimethate Sodium in the Treatment of Subjects With Non-cystic Fibrosis Bronchiectasis Chronically Infected With Pseudomonas Aeruginosa (P. Aeruginosa)

Lay Title: Long Term Efficacy and Safety of Inhaled Colistimethate Sodium in Bronchiectasis Subjects With Chronic Pseudomonas Aeruginosa Infection. (PROMIS-I)
Click here for more information


2. Protocol: RTB101-204 (PI: Dr Rachel Thomson)
Short Title: The PROTECTOR Study

Protocol Title: A Multicenter, Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Determine if RTB101 Prevents Clinically Symptomatic Respiratory Illness in the Elderly

Lay Title: Effect of RTB101 on Respiratory Illness Associated with Laboratory-Confirmed Pathogens in the Elderly
Click here for more information

 


 

Our Team

Resources

View Resources